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Abstract
In this chapter, the novel findings on interrelationship between vitamin D status and
two well‐known prothrombotic  states,  antiphospholipid  syndrome,  particularly  its
thrombotic phenotype, and metabolic syndrome will be reviewed. We shall present the
results  obtained  from  patients  included  in  Serbian  National  Antiphospholipid
Syndrome Registry, 68 patients with primary antiphospholipid syndrome (PAPS) and
69  patients  with  antiphospholipid  syndrome  associated  with  certain  autoimmune
rheumatic disease (sAPS), as well as 50 patients with pure metabolic syndrome (MetS).
These results will be analysed and compared with the novel literature data. Prevalence
of  MetS in APS is  high,  with the atherogenic  dyslipidaemia as  its  most  prevalent
characteristic. Prevalence of thrombotic events was significantly higher in APS patients
with  coexisting  MetS,  compared  with  those  without  MetS.  Among  APS  patients,
prevalence of VitD deficiency was significantly higher than in patients with pure MetS.
VitD level was also significantly lower in APS patients with coexisting MetS or previous
thrombotic events than in those without them. Elucidating interrelationships between
VitD deficiency, MetS and thrombotic events in APS patients open up the possibility of
distinguishing those subjects with the particularly high cardiovascular risk and ensuing
need for the strict control of modifiable risk factors and VitD supplementation.
Keywords: vitamin D, antiphospholipid syndrome, metabolic syndrome, classifica‐
tion criteria, thrombosis
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1. Introduction
The  antiphospholipid  syndrome (APS),  primary  or  associated  with  certain  autoimmune
rheumatic diseases, especially systemic lupus erythematosus, represents prothrombotic state.
Coexistence of metabolic syndrome (MetS) and autoimmune rheumatic diseases is already
recognized [1, 2], while clinical significance of MetS in patients with APS has not been system‐
atically studied [3]. Recent recognition of certain pleiotropic functions of vitamin D (VitD) has
enabled us to hypothesize on its role in the pathogenesis of obesity, MetS, APS, autoimmunity
and thrombosis. Therefore, the aim of this review will be: (1) to clarify the possible linking role
of VitD between APS and MetS, (2) to critically assess the need for estimation of VitD status in
APS patients, depending on the coexistence of MetS and (3) to explore the potential therapeutic
role which VitD, as an immunomodulator and anti‐thrombotic agent, could have in these
patients.
2. Basic definitions
Metabolic syndrome (MetS) and antiphospholipid syndrome (APS) are among most prevalent
and still highly controversial syndromes. While clinical relevance of antiphospholipid
antibodies (aPL) was recognized more than 30 years ago, definite classification criteria for
antiphospholipid syndrome were given at the International Workshop in Sapporo, Japan 1998
[4] and revised 2006 in Sidney, Australia [5]. Very interesting proposal of APS criteria based
on biological mechanisms is presented lately aiming at simplicity and greater accuracy and,
at the same time, avoiding non‐specific formulations [6] (Table 1). Recent investigations have
also shown that, beside characteristic thrombotic or obstetric symptoms, there is growing
number of systemic non‐criteria manifestations (for example, thrombocytopenia, livedo
reticularis, skin ulcerations, pseudovasculitis, migraine and epilepsy) correlating with certain
type of aPL and with important predictive role [7, 8]. It is likely that a prominent place among
these manifestations belongs to components of MetS, but it is still to be proved. The prevalence
of APS in the general population is estimated to be around 2–4%.
Initial Reaven's postulate in 1988, which draw attention to the causal association between
insulin resistance with ensuing hyperinsulinemia and cardiovascular diseases [9], was
followed by numerous definitions of MetS. Three of them, i.e. definitions given by World
Health Organization (WHO) [10], the National Cholesterol Education Program Adult
Treatment Panel III (NCEP ATP III) [11] and International Diabetes Federation (IDF) [12], were
most frequently used and still neither of them is obsolete. While all three definitions share
central obesity, atherogenic dyslipidaemia and arterial hypertension as common criteria, WHO
definition put the insulin resistance in focus of metabolic syndrome while an obligatory
criterion requested by IDF definition is elevated waist circumference (WC) with population‐
and country‐specific cut‐offs (Table 2). All of these three definitions are very similar but
different enough, especially when used for the assessment of prevalence of MetS in some other
entities, in this case, among patients with APS. Even the latest joint attempt of several major
A Critical Evaluation of Vitamin D - Clinical Overview182
professional organizations (the IDF Task Force on Epidemiology and Prevention, National
Heart, Lung and Blood Institute, American Heart Association, World Heart Federation,
International Atherosclerosis Society and International Association for the Study of Obesity)
to unify interconnected cardio‐metabolic risk factors into a universal definition of metabolic
syndrome did not seem to be final [13].
Table 1. Antiphospholipid syndrome definitions.
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Similar ambiguity exists concerning the definition of adequate circulating VitD level, as well
as of its deficiency and insufficiency. Earlier definition of VitD insufficiency by its blood level
of <20 ng/mL (50 nmol/L), given by the World Health Organization (WHO) [14], has been
recently accepted by most researchers as a definition of the deficiency of this vitamin [15, 16].
Its insufficiency is defined as a VitD concentration between 20 and 30 ng/mL (50 and 75 nmol/
L), while its concentrations >30 ng/mL (75 nmol/L) are regarded as sufficient [17, 18].
The WHO definition10 NCEP ATP III definition11 IDF definition12
Insulin resistance
plus ≥ 2 of:
≥ 3 of:
Central obesity plus 2 of:
Atherogenic dyslipidaemia
Hypertension
Microalbuminuria Impaired fasting glucose/Glucose intolerance/Diabetes
Table 2. Metabolic syndrome definitions—similar but different enough.
3. Experience from Serbian National APS Registry
3.1. Patients and methods
Study included a total of 137 APS patients, attending outpatient clinic of the University Medical
Center Bezanijska kosa, all Caucasians, who were previously enrolled in Serbian National APS
Registry. These patients represented only the part of those so far included in this Registry,
which is still growing and is still unable to appraise the prevalence of APS among general
population in Serbia. Among studied patients, 68 were PAPS patients (59 females, nine males,
mean age 43.51+10.58 years) and 69 sAPS patients (61 females, eight males; mean age
47.83+15.67 years). All studied APS patients have met 2006 updated Sydney criteria [5] which
requested the presence of at least one clinical criteria (i.e. vascular thrombosis or multiple and
recurrent foetal losses) and at least one of antiphospholipid antibodies (aPL), i.e. lupus
anticoagulant (LA), anticardiolipin (aCL) and/or anti‐β2‐glycoprotein 1 (β2GP1) antibodies.
Most of our sAPS patients had APS associated with systemic lupus erythematosus (SLE) (n=60;
87%), while the rest had Sjögren's syndrome (n=8; 11.5%) and ankylosing spondylitis (n=1;
1.5%). Mean duration of these rheumatic diseases in sAPS patients was 5.69+2.87 years, ranging
from 1 to 13 years.
Characteristics of two subgroups of APS patients were compared with 50 MetS patients (35
females, 15 males; mean age 47.68+11.66 years). The presence of metabolic syndrome among
studied patients was determined according to the International Diabetes Federation (IDF)
clinical definition [12]. An obligatory criterion for MetS requested by this definition is ab‐
dominal obesity defined by elevated waist circumference (WC) with gender‐ and ethnic‐
specific cut‐offs, meaning 94 cm for males, and 80 cm for females belonging to European
population. Besides abdominal obesity, two or more of the four additional criteria (a) hyper‐
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triglyceridemia >150 mg/L, confirmed or already treated; (b) high density lipoprotein (HDL)
cholesterol <40 mg/dL in males or <50 mg/dL in females; (c) blood pressure >130/85 mmHg,
newly diagnosed or already treated; (d) impaired fasting glycaemia, >100 mg/dL or previously
diagnosed diabetes) are necessary for the diagnosis.
For every participant, clinical data concerning thrombotic events, their appearance, manage‐
ment and follow‐up were obtained from medical charts review. As thrombotic events, the
following were recorded: superficial and deep venous thrombosis, pulmonary embolism,
peripheral arterial occlusion, cerebral vascular accident and myocardial infarction.
After an overnight fast, height (m), weight (kg) and waist circumference (cm) were measured
in every participant with underwear and without shoes. Waist circumference (WC) was
measured at the level of the umbilicus while the participant was standing and breathing
normally. Body mass index (BMI) was calculated according to the widely accepted formula
dividing body weight by the square of individual's height. Morning samples of venous blood
(3–5 mL) were withdrawn from every participant for the analysis of serum glucose and lipids.
Serum vitamin D levels were determined in every participant .
The study was approved by the Institutional Ethics Committee. All examinations were
conducted according to the most recent amendment of Declaration of Helsinki (Edinburgh,
2000), only after obtaining an informed consent for participation in the study from every
subject.
Statistical analysis was performed using the STATISTICA 10 software program. Descriptive
statistics was used. Prevalence of MetS as well as of its individual components, within studied
groups of patients was expressed as percentage. Testing significance of their differences, the
Student's t‐test and Fisher's exact test were used, considering p value <0.05 statistically
significant.
3.2. Results
3.2.1. Prevalence of MetS among patients with APS
Metabolic syndrome was observed in high percentage of patients with APS. Its prevalence did
not differ significantly between PAPS (36.76%) and sAPS (42.03%) patients (p=0.53).
Anthropometric and metabolic syndrome characteristics among studied groups are given in
Table 3. Borderline statistical significance of the difference in WC value was observed when
two subgroups of APS patients were compared with MetS patients (F=2.77, p=0.065), while
BMI has differed highly significantly between these groups (F=9.765, p=0.0001). In spite of
slightly lower BMI and slightly higher WC in PAPS patients, neither BMI (p=0.434) nor WC
(p=0.275) did differ significantly between two subgroups of APS patients.
Atherogenic dyslipidaemia, represented by hypertriglyceridemia and low HDL cholesterol,
was the most prevalent characteristic of metabolic syndrome among PAPS patients. In spite of
this, prevalence of low HDL cholesterol among PAPS patients were significantly lower than
in MetS patients (48.3% vs. 70%, p=0.02). Prevalence of hypertriglyceridemia (45.59% vs.
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42.03%, p=0.67) and low HDL cholesterol (48.53% vs. 53.62%, p=0.55) did not differ significantly
between PAPS and sAPS patients. Hypertension was significantly less prevalent among these
patients compared with MetS (23.53% vs. 58%, p=0.0002) and even with sAPS (23.53% vs.
52.17%, p=0.0007) patients. The least prevalent characteristic of metabolic syndrome among
patients with APS was hyperglycaemic disorder. Compared with MetS patients in whom
impaired fasting glycaemia, glucose intolerance or diabetes were present in as much as 36%,
these disorders were observed in only 5.88% of PAPS patients (p=0.0001) and 4.35% of sAPS
patients (p<0.0001).
MetS PAPS sAPS
BMI (kg/m2) 32.09+6.14 27.81+5.98 28.54+4.22
WC (cm) 93.67+14.36 90.73+9.18 88.53+11.91
TG > 150 mg/dL (%) 58 45.59 42.03
HDL < 40/50 mg/dL (%) 70 48.53** 53.62
Hypertension (%) 58 23.53**** 52.17§§
IFG, IGT, DM (%) 36## 5.88**** 4.35
*p < 0.05, PAPS vs. MetS.
**p < 0.01, PAPS vs. MetS.
#p < 0.01, sAPS vs. MetS.
§p < 0.01, PAPS vs. sAPS.
Table 3. Anthropometric and metabolic syndrome characteristics among studied groups.
3.2.2. Prevalence of thrombotic events among APS patients with or without MetS
Compared with patients with metabolic syndrome, prevalence of thrombotic events was
significantly higher among patients with PAPS (52.94% vs. 22%, p=0.0009) and sAPS (56.52%
vs. 22%, p=0.0003). Thrombotic events were reported with similar prevalence in PAPS and
sAPS patients (p=0.674).
When compared with APS patients without characteristics of MetS, thrombotic events were
significantly more frequent among MetS positive patients with sAPS (75.86% vs. 42.5%,
p=0.0075).
Although higher among MetS positive, compared with MetS negative patients with PAPS,
difference of prevalence of thrombotic events among these two subgroups of PAPS patients
did not reach statistical significance (68% vs. 44.19%, p=0.0622).
3.2.3. Vitamin D status among APS patients depending on MetS and/or thrombotic events
Low VitD status (insufficiency or deficiency) was highly prevalent among PAPS (insufficiency
in 27.94% and deficiency in 36.76%) and sAPS patients (insufficiency in 30.43% and deficiency
in 40.58%), as well as among patients with pure MetS (insufficiency in 20% and deficiency in
32%).
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In comparison with patients with pure MetS (28.58+14.32 ng/mL), VitD concentrations were
lower in PAPS (25.76+12.18 ng/mL) and sAPS patients (23.81+11.22 ng/mL), but with statisti‐
cally significant difference only between these concentrations in sAPS patients and patients
only with MetS (p=0.04).
Significantly lower VitD level was observed in those with coexisting MetS (MetS +), compared
with those without it (MetS ‐) both in PAPS (MetS +: 22.0+8.52 vs. MetS ‐: 27.0+13.49 ng/mL,
p=0.05 ) and sAPS patients (MetS +: 18.83+9.16 vs. MetS ‐: 27.42+11.28 ng/mL, p=0.0012).
Also, significantly lower VitD level was observed in APS patients with thrombotic events
(TE+), compared with those without these events (TE ‐), both in PAPS (TE +: 20.61+12.18 vs.
TE ‐: 31.56+12.72 ng/mL, p=0.0001 ) and sAPS patients (TE +: 20.67+10.43 vs. TE ‐: 27.9+11.04 
ng/mL, p=0.007).
In 11 (22%) of patients with MetS, but without APS, some thrombotic event was confirmed. In
those patients, VitD levels were also significantly lower than in those without these events (TE
+: 18.45+10.66 vs. TE ‐: 31.43+13.63 ng/mL, p=0.003).
However, both in PAPS and sAPS patients, with coexisting MetS, previous thrombotic events
did not influence serum VitD levels (PAPS: p=0.12; SAPS: p=0.93).
4. Relationship between antiphospholipid syndrome and metabolic
syndrome
Estimation of prevalence of MetS in general population seems to depend to a substantial degree
on the used definition, at least in certain countries or in certain ethnic groups [19–22]. Its
prevalence varies between <10% in China and as much as 60% among women of Samoa [23].
Different prevalences of MetS, ranging between 18 and 48%, were also recorded among
populations of different European countries and regions [20–22, 24–26]. It is interesting to
emphasize that even in populations in which comparable prevalence of MetS was found using
each of three already mentioned definitions, level of agreement between them was not good.
As could be expected, worse agreement was found between WHO‐NCEP ATP III and WHO‐
IDF than between NCEP ATP III‐IDF definitions because of the central obesity as common
denominator of the last two definitions [20, 21, 23]. This observation raised the possibility that
in fact different individuals were identified as having MetS by different definitions of this
syndrome [23].
In a search for factors that contribute to the manifestations of APS, MetS came into a focus
surprisingly late. Data on coexistence of these two syndromes are still relatively scarce,
particularly considering that of MetS and primary APS (PAPS).
4.1. Metabolic syndrome in primary antiphospholipid syndrome patients
Recently, prevalence of MetS among PAPS patients has been assessed by Medina et al. [3] and
Rodrigues et al. [27]. Both surveys were performed in Hispanics among whom MetS has the
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highest prevalence [28]. Defined by the IDF criteria, the prevalence of MetS among 71 Brazilian
PAPS patients was 33.8% [27]. Comparable prevalences of MetS were recorded among 58
Mexican PAPS patients, using NCEP ATP III (34.5%) or IDF definitions (37.9%), while it was
only 17.2% when WHO definition was applied [3]. It has been hypothesized that these cases,
identified by WHO definition, were insulin resistant and with more severe forms of MetS [3,
29]. However, in investigation conducted by Medina et al., prevalence of MetS among PAPS
patients was higher than in corresponding general population (17.2% vs. 13.6%) when WHO
definition was used [3]. Same as in general population without APS [20, 21, 23], among PAPS
patients agreement between WHO and NCEP ATP III definitions of MetS was low (κ value
0.394), moderate between WHO and IDF definitions (κ value 0.427), while only between NCEP
ATP III and IDF definitions agreement was good (κ value 0.851) [3].
Regarding individual components of MetS, atherogenic dyslipidaemia was most prevalent
among Mexican PAPS patients, being present in approximately half of them [3]. Significantly
higher mean triglyceride levels and significantly lower mean HDL levels were previously
reported among PAPS patients in comparison with controls [30–33]. Some specific autoanti‐
bodies could influence lipoprotein levels and effects in these patients. These antibodies may
interfere with paraoxonase (PON) activity of HDL and, indirectly, beta‐2‐glycoprotein I (beta‐
2‐GPI) [32, 33], thus promoting LDL oxidation. Relationships between lipid profile, certain
anti‐lipoprotein antibodies, inflammatory markers and clinical manifestations of PAPS were
meticulously investigated [31–33], but on relatively small number of patients and with
inconsistent results. Delgado Aves et al. have not demonstrated any correlation between the
observed decrease in PON activity and either aPL nor antibodies against HDL (anti‐HDL) in
PAPS patients [33]. However, pro‐inflammatory and prothrombotic roles were proposed for
anti‐HDL, being present in higher titre among asymptomatic persistently aPL positive
subjects, as well as in PAPS patients with thrombotic events, when compared with patients
with inherited thrombophilia and healthy controls [32]. It has been also hypothesized that
hypertriglyceridemia could be the result of decreased degradation as a consequence of an
inhibition of lipoprotein lipase (LPL) by aPL [3]. Currently, there are only scarce data on
prevalence of antibodies against LPL (anti‐LPL) in PAPS patients, speaking against their
existence and influence [31].
Different authors have observed similar prevalences of hypertension among PAPS patients
(22.4 and 26.3%) [3, 31], not differing significantly from that in controls (20%). Nevertheless,
among PAPS patients, hypertension was significantly more frequent in those with arterial
thrombosis, with which it was independently associated [31]. It is interesting that in spite of
highly prevalent insulin resistance (32.8%), hyperglycaemic disorders were present in only 5%
of PAPS patients [3].
4.2. Metabolic syndrome in patients with antiphospholipid syndrome associated with
autoimmune rheumatic diseases.
The literature data on coexistence of MetS and numerous rheumatic diseases (i.e. systemic
lupus erythematosus, rheumatoid arthritis, Sjögren's syndrome, ankylosing spondylitis,
osteoarthritis, gout) are fairly extensive [1, 34–42]. The prevalence of MetS among patients with
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these disorders ranges between 14 and 62.8% [1, 3]. Qualifier “antiphospholipid syndrome
associated with certain autoimmune rheumatic disease” (sAPS), which replace currently
obsolete term “secondary APS”, refers mainly to the systemic lupus erythematosus (SLE)
despite the still unscrambled puzzle of their relations [5].
It has been speculated that high prevalence of MetS among these patients might be the
consequence of certain pharmacologic interventions, particularly of chronic corticosteroid
therapy [43]. However, the presence of MetS in as much as 16% of 1494 young (35.2+13.4 years)
SLE patients with rather short disease duration (24.1+18.0 weeks) seems to be enough to reject
this relationship as causal [2]. Nevertheless, it should be kept in mind that duration and
magnitude of corticosteroid exposure could aggravate well‐known cardiovascular risk factors
clustering as characteristics of MetS.
On the other hand, other pharmacological interventions, primarily methotrexate (MTX) use in
patients with rheumatoid arthritis, have been depicted as independent factors for reduced
prevalence of MetS in these patients, especially those older than 60 years [44, 45]. This beneficial
effect of MTX was attributed to its anti‐inflammatory, as well as to some still unclear drug‐
specific effects, i.e. affecting adenosine levels and, concomitantly, glucose and lipid metabo‐
lism, or decreasing homocysteine levels as an indirect effect of simultaneous use of folic acid
[44]. However, other authors reported somewhat conflicting results not being able to confirm
decreasing prevalence of MetS in subjects treated with MTX, among total of 353 patients with
rheumatoid arthritis [46].
5. Vitamin D and thrombosis
Prothrombotic state is one of the well‐known characteristics of both antiphospholipid and
metabolic syndrome. It has rather complex pathogenesis in which VitD status has an important
role affecting primarily immune‐mediated thrombosis. Indirect proofs for this relationship are
as follows: (a) existence of nuclear VitD receptors in vascular smooth muscle cells, endothelial
cells, cardiomyocytes, platelets, as well as in most types of the immune cells [47–51], and (b)
expression of cytochrome P450 enzyme, CYP27B1 activity by the same cell types, enabling
local synthesis of biologically active form of VitD, 1,25(OH)2D [52].
There is substantial experimental data indicating that VitD plays significant role in mainte‐
nance of physiological balance between thrombosis and haemostasis [47]. It has been demon‐
strated that VitD exerts following actions:
• in monocytes, expression of tissue factor (TF) is downregulated, while the expression of
thrombomodulin (TM) is upregulated [53];
• in vascular smooth muscle cells, the expression of TM is upregulated, but there is also
downregulation of plasminogen activator inhibitor‐1 (PAI‐1) and thrombospondin‐1
(THSP‐1) [54];
• in endothelial cells, platelet activation is attenuated as well as the expression of vascular cell
adhesion molecule‐1 (VCAM‐1) [55].
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Net result of numerous effects of this vitamin on different haemostatic factors is its antith‐
rombotic role. Prothrombotic state that exists in VitD receptor knockout animal models proves
the importance of these extra‐skeletal effects of VitD as well as the observation that all of them
are VitD receptor‐mediated [47, 56].
However, there are still relatively few indirect and even less direct clinical evidences for the
association between VitD status and thrombotic events in humans. First of them came from
the epidemiological studies in which have been observed that cardiovascular morbidity and
mortality depended on season of the year and latitude [47, 57, 58]. Seasonal variations were
also demonstrated for tissue plasminogen activator (tPA) antigen, fibrinogen, D‐dimer and
von Willebrand factor (vWF) concentrations in 6538 British subjects without significant
cardiovascular disorders, aged 45 years [59]. In this population, negative correlation between
VitD level and tPA, fibrinogen and D‐dimer concentrations was observed indicating that at
least some of the seasonal variations of these thrombotic markers could be attributed to the
VitD status. More direct proof for the association between VitD status and thrombosis came
from the research conducted in huge population of 18 791 subjects from general population of
Copenhagen [60]. Authors have observed that every quartile of a decrease in VitD concentra‐
tions was accompanied by an increase in risk of venous thromboembolism (VTE), resulting in
a 37% increased VTE risk between subjects with the VitD concentrations, in the lowest quartile
and those in highest quartile.
Recent publication which retested the seasonality of different cardiovascular events in regard
to VitD levels, in the Scottish Heart Health Extended Cohort (SHHEC), brings a dose of
confusion in previously proposed relations. Namely, it failed to prove that seasonal appearance
of cardiovascular events resembled seasonal variations in serum VitD concentrations nor that
these events expressed more pronounced seasonality in those with lower VitD concentrations,
compared with those with its higher concentrations [61]. But, during follow‐up, significant
correlations were observed between lower baseline concentrations of VitD and subsequent
incident cardiovascular morbidity and incident cardiovascular and all‐cause mortality [61].
Results of recent trials assessing the effects of VitD supplementation on the risk of throm‐
boembolism were inconclusive [62–64]. In the Multiple Environmental and Genetic Assess‐
ment (MEGA) case‐control study which included 2506 patients with venous thrombosis,
thrombotic risk was 37% lower in those supplemented with various vitamins including VitD
[62]. However, in a large cohort of postmenopausal women (n=36282) from the Women's
Health Initiative, daily supplementation with calcium and VitD failed to reduce the overall
risk of thromboembolism [63]. Even when high doses (300,000 IU) of VitD were given intra‐
muscularly, in a small group of patients with proven deep vein thrombosis and pulmonary
embolism, observed reduction in plasma concentrations of P‐selectin and high‐sensitive C‐
reactive protein (hs‐CRP) did not reached statistical significance [64]. Additional information
could be expected from the ongoing Vitamin D and OmegA‐3 Trial (VITAL) and that is why
the results of this investigation are eagerly awaited [65].
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6. Role of vitamin D in metabolic syndrome
Currently, increasing prevalence and co‐existence of obesity, MetS and hypovitaminosis D
represent serious public health concern [66, 67]. New data have considerably changed
hierarchy of MetS components, with the shift of the focus from obesity and insulin resistance,
firstly toward fatty liver and now toward VitD deficiency [68].
It is still questionable if relationship between VitD status and obesity is unidirectional or
bidirectional, with the accumulating evidence favouring the influence of VitD on body
composition and not vice versa. Namely, few years ago tempting hypothesis on essential role
of VitD in evolvement of obesity has been postulated [68]. It started from a situation that is
completely opposite to the “thrifty genotype hypothesis” proposed long ago [69] and gave the
feasible explanation not only for obesity and MetS epidemic in adults but also for their growing
prevalence among children [70]. According to this hypothesis, we are living in “obesogenic”
environment, loaded with energy resources and unsuitable for efficient metabolism. It has been
proposed that VitD as an ultraviolet (UV)‐B radiation sensor (i.e. decline in its concentrations)
could induce shift toward “winter metabolism”, characteristic for MetS [68]. If this is true, then
it could be expected that VitD supplementation may be efficient in prevention and treatment
of obesity and MetS. Significant decrease in body fat mass after 12 week of VitD repletion
(25 μg of cholecalciferol daily), compared to placebo (−2.7+2.0 kg vs. −0.4+2.0 kg, p<0.001),
could be the proof for this presumption [71]. It was also speculated that VitD deficiency during
pregnancy could lead to the epigenetic changes predisposing, in that manner, new‐born
children to obesity and MetS later in life [68, 70]. Experimental support for these assumptions
is the expression of VitD receptors on adipocytes and its involvement in adipogenesis which
is regulated by the intracellular concentrations of VitD [72], as well as inhibition of lipid
accumulation in adipocytes and their atrophy achieved by the knock‐down of VitD receptors
[72, 73].
Nowadays, VitD deficiency is common even in general population (49%), but significantly
more prevalent (p=0.006) and quite similar in overweight/obese patients with MetS (72%) and
without MetS (69%) [74]. Premise that exaggerated adiposity could lead to VitD insufficiency
or deficiency by its seclusion within adipose tissue could not be confirmed. It has been shown
that VitD concentrations varied considerably (range 4–2470 ng/g) in the subcutaneous ab‐
dominal fat of 17 severely obese patients (BMI=48.7+8.1 kg/m2) undergoing bariatric surgery
[75]. In spite of the average weight loss of 54.8 kg after one year and continuous VitD supple‐
mentation with more than 2500 IU/day, mean serum VitD concentrations did not change
significantly during this period (23.1+12.6 vs. 26.2+5.36, p=0.58) [75].
Most of the studies have confirmed that serum VitD concentrations significantly inversely
correlated with obesity parameters, BMI (r=‐0.159, p=0.007) [74], or waist circumference
(p<0.001) [76] as well as with serum triglycerides (r=‐0.149, p=0.012) [76]. In the lowest quartiles
of VitD concentrations corresponding to its severe deficiency, odds ratio (OR) for hypertrigly‐
ceridemia was 2.74 (95% CI: 1.64–4.57) [77]. This association between serum concentrations of
VitD and triglycerides could be explained by the activation of lipoprotein lipase by VitD in
adipocytes [76]. No significant relation could be demonstrated between VitD status and total‐
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(r=‐0.044, p=0.461) [74], low density lipoprotein (LDL)‐ (r=‐0.005, p=0.932) and high density
lipoprotein (HDL)‐cholesterol (r=0.065, p=0.276) [74]. Interestingly, hypothesis was proposed
ten years ago stating the possibility that statins could be the analogues of VitD, acting via same
receptors, particularly when we are talking about their mutual effect of enhancement of
immune competence [78]. So, it seems that this absence of association between VitD status and
parameters of cholesterol metabolism made this hypothesis shaky to some extent.
Another component of MetS for which association with VitD status has not been unequivocally
confirmed is hypertension. Variability of blood pressure driven by the seasons or latitude
speaks for the existence of this association, as well as the results of experimental studies
pointing to VitD as an inhibitor of the renin‐angiotensin‐aldosterone axis [79, 80]. Negative
correlation between VitD concentrations and blood pressure was demonstrated in most but
not all of the surveys. This negative association was stronger in subjects younger than 50 years
[81–83], while the absence of any relationship between VitD status and hypertension was also
registered in some of the trials [74, 76, 84, 85], particularly those conducted in older subjects
[84, 85]. However, in postmenopausal women with the VitD concentrations in the lowest
quartiles corresponding to its severe deficiency, odds ratio (OR) for hypertension was 1.81 (95%
CI: 1.15–2.85) [77].
7. Role of vitamin D in antiphospholipid syndrome
Although APS represents acquired, autoimmune condition, its pathophysiology and, espe‐
cially pathophysiology of thrombosis in APS is highly heterogeneous, involving different
genes and acquired factors [86], VitD insufficiency/deficiency being among them.
Same as for relationship between MetS and APS, much more is known about the impact of
VitD status on antiphospholipid syndrome, associated with autoimmune rheumatic diseases,
than on primary antiphospholipid syndrome. Patients with PAPS represent the population of
particular interest for the investigation of interrelations with components of MetS and/or VitD
status since these patients, unlike those with sAPS, were not treated with drugs (i.e. cortico‐
steroids, immunosuppressants) which may affect expression of most of the MetS characteris‐
tics as well as VitD level.
One of the first announcements on the prevalence of VitD insufficiency or deficiency in PAPS
and their impact on its manifestations dated from 2010 [87]. This letter to the editor presented
the results of research conducted by Brazilian investigators in the group of forty‐six PAPS
patients, younger than 60 years, in whom the VitD levels were assessed in the autumn, when
it was expected to be highest. VitD deficiency was found in 11% and insufficiency in 74% of
these PAPS patients, resembling the findings of Italian authors [88] which have reported the
prevalence of VitD deficiency in 17% and insufficiency in 60% of PAPS patients. It is interesting
that Brazilian authors have noticed that VitD insufficient PAPS patients tended to be more
overweighed than those with adequate VitD level [87]. Also, it seems that thrombotic APS is
characterized with significantly lower concentrations of VitD than purely obstetric clinical
syndrome (20.8 vs. 33.3 ng/ml, p<0.01) [88] highlighting once again the role of this vitamin in
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thrombosis. High prevalence of VitD deficiency among patients with APS (49.5%) and its
significant correlation with thrombotic events were confirmed by Israeli authors [68]. In vitro,
they have also demonstrated VitD ability to inhibit anti‐β2‐glycoprotein I autoantibody (anti‐
β2‐GPI Ab)‐mediated TF expression [89].
Seasonal variations in VitD concentrations were demonstrated in PAPS patients same as in
healthy controls, with preserved differences in its level between these two groups through all
seasons [88, 90]. These differences were most pronounced during summer, while they were
not statistically significant only during the spring. This observation was somewhat surprising,
given the lack of banning from sun exposure in these patients. That sun avoidance is not a
cause of highly prevalent VitD deficiency and insufficiency in PAPS patients was indirectly
demonstrated in previous Italian studies [88, 90] by observed absence of any difference in VitD
levels between antinuclear antibodies (ANA)‐positive and negative PAPS patients.
Until now, there is no valid explanation for the probable cause‐and‐effect relationship between
insufficient VitD level, on one side, and PAPS or sAPS, on the other. There are only assump‐
tions, and even they are much better clarified for sAPS [91–93], especially that accompanying
SLE [91, 94, 95]. It is obvious that low levels of vitamin D in sAPS could not be attributed purely
to banning of sun exposure or the use of certain medication in these patients. In an Israeli and
European cohort of patients with SLE, significant negative correlation (r=‐0.12, p=0.018) was
demonstrated between the serum VitD concentrations and disease activity, assessed by SLE
disease activity‐2000 (SLEDAI‐2K) and European Consensus Lupus Activity Measurement
(ECLAM), which were converted into standardized z‐value [94]. Severe VitD deficiency was
found in 17.89% of 123 SLE patients with short disease duration, while the presence of renal
disease (OR 13.3, 95% CI 2.3–76.7, p<0.01) and photosensitivity (OR 12.9, 95% CI 2.2–75.5,
p<0.01) were its strongest predictors [95]. Investigation conducted in a small group of young
women with newly diagnosed SLE, from one of the sunny places in Iran, gave very interesting
results. VitD deficiency was highly prevalent among these patients, mild in 12.5%, moderate
in 62.5% and severe in 17.5% of them [96]. It was much more pronounced in them than in
general population of the similar age in that region, in whom mild VitD was present in 15.5%,
moderate in 47.1% and severe in 7.1%. Very interesting was also an observation that serum
VitD concentrations showed significant negative correlation with another disease activity
score, the British Isles Lupus Assessment Group (BILAG) (r=‐0.486, p=0.001), in spite of the
short duration of disease [97]. Hypothetical explanation for the low serum concentrations of
VitD in SLE patients by the existence of inhibiting anti‐VitD antibodies in circulation could not
be confirmed by the literature data [97, 98]. Their existence could be proven in 4–6% of patients
with SLE and 3.5% of APS patients. Its association with anti‐dsDNA (p=0.0004) could point to
its potential role in this condition, but being only one of 116 different antibodies present in SLE
patients characterized by the polyclonal B lymphocyte activation, it is still uncertain if it is
pathogenic [97]. It seems that their presence did not affect VitD levels in these patients [97,
98], and it was speculated that they could be the consequence of high‐dose VitD consumption
rather than the cause of this vitamin deficiency [99].
Once again, it is important to emphasize that VitD deficiency is more pronounced in more
severe APS phenotypes, i.e. thrombotic APS [88]. It could be speculated that supplementation
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of this vitamin in these very patients may have certain beneficial effects [88, 99], but there is
still no prospective studies proving them. Hypothesis of statins as VitD analogues has not still
been tested in well‐designed, randomized prospective trials [78]. However, since its proposal,
there have been many experimental and small clinical studies confirming statins therapeutic
value in APS patients, particularly in those with its thrombotic form [99–103]. So, future studies
are badly needed to determine all the aspects of VitD repletion in APS prevention/therapy
(choice between VitD precursors, its active form or VitD analogues, their dosage and treatment
goals).
8. Key messages
• Prevalence of metabolic syndrome in APS, primary or associated with certain rheumatic
diseases, is high.
• Atherogenic dyslipidaemia is the most prevalent characteristic of metabolic syndrome in
APS patients.
• Prevalence of thrombotic events was significantly higher in APS patients with coexisting
metabolic syndrome, compared with APS patients without metabolic syndrome character‐
istics.
• Among APS patients, prevalence of vitamin D deficiency was significantly higher in patients
with coexisting metabolic syndrome, compared with those without it.
• Among APS patients, vitamin D level was also significantly lower in patients with previous
thrombotic events than in those without them.
• In the contemporary literature, there are much more data in favour of pathogenic than
therapeutic role of vitamin D in thrombotic events characterizing APS and/or metabolic
syndrome. So, prospective studies designed to test all the aspects of VitD repletion in
prevention and/or therapy of thrombotic events in APS and/or metabolic syndrome are
badly needed.
9. Conclusions
Elucidating interrelationships between vitamin D deficiency, metabolic syndrome phenotype
and thrombotic events in APS patients open up the possibility of distinguishing those subjects
with the particularly high cardiovascular risk and ensuing need for the strict control of
modifiable risk factors and vitamin D supplementation.
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